Clinical Trial Update: Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the cardiac and metabolic effects of semaglutide in heart failure with preserved ejection fraction (HFpEF) and obesity is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Heart Failure with Preserved Ejection Fraction
• Obesity

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Mayo Clinic | Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Status: ENROLLING_BY_INVITATION